Vaccine, rabies


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Preexposure prophylaxis against rabies 1 mL on days 0, 7 and on day 21 or 28. Booster: Persons at regular or continuous risk: 1 mL given 1 year after completion of primary course, then 1 mL every 3-5 years. Persons at intermittent risk: Doses are given based on official recommendations. Postexposure prophylaxis of rabies Unimmunised or incompletely immunised persons: 1 mL on days 0, 3, 7, 14, and on day 28 or 30. Fully immunised persons: 1 mL on day 0 and 3.

Dosage Details
Intramuscular
Preexposure prophylaxis against rabies
Adult: Primary immunisation: 1 mL on days 0, 7 and 28 (3rd dose may be given on day 21 if needed). Booster: Persons at regular or continuous risk: 1 mL given 1 year after completion of primary course, then 1 mL every 3-5 years. Persons at intermittent risk: Doses are given according to official recommendations.
Child: Same as adult dose.

Intramuscular
Postexposure prophylaxis of rabies
Adult: Unimmunised or incompletely immunised persons: 1 mL on days 0, 3, 7, 14, and 28; alternatively, the 5th dose may be given on day 30. Fully immunised persons: 1 mL on day 0 and 3.
Child: Same as adult dose.
Contraindications
Hypersensitivity (when used for pre-exposure prophylaxis). Severe immunosuppression.
Special Precautions
Patient with acute or minor illness, personal or family history of febrile convulsions, history of bleeding disorders (e.g. thrombocytopenia). Postpone vaccination in case of febrile or acute illness. Very premature infants or those with history of respiratory immaturity. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Serum sickness, syncope, bleeding haematoma, multiple sclerosis, meningitis, myelitis, retrobulbar neuritis, convulsion, transient paralysis. Rarely, Guillain-Barre syndrome.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting.
General disorders and administration site conditions: Inj site reactions (e.g. bruising, pruritus, erythema, induration), pyrexia, malaise, chills, irritability.
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Dizziness, headache.
Respiratory, thoracic and mediastinal disorders: Dyspnoea, wheezing.
Potentially Fatal: Anaphylactoid or hypersensitivity reactions, encephalitis.
IM/Parenteral: C
Drug Interactions
Diminished efficacy when given with antimalarials, corticosteroids, and other immunosuppressants. Increased risk of bleeding or haematoma with anticoagulants.
Action
Description: Rabies vaccine is an inactivated virus vaccine that is used for active immunisation against rabies. It promotes immunity by inducing an active immune response. It can be used for pre- and post-exposure immunisation. For post-exposure immunisation, it is often used in conjunction with rabies immunoglobulins as it takes about 7-10 days for the specific antibodies to develop.
Onset: IM: Rabies antibody: Approx 7-10 days.
Duration: ≥1 year.
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07BG - Rabies vaccines ; Used for active immunizations.
References
Anon. Rabies Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/07/2018 .

Buckingham R (ed). Rabies Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/07/2018.

Joint Formulary Committee. Rabies Vaccine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/07/2018.

Rabavert (GlasoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, rabies from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in